What Selincro Treats: Main Uses and Benefits

Selincro is a specific prescription medication generally used to manage key aspects of alcohol dependence in adult patients. Its therapeutic use plays a role in managing the symptoms that interfere with the patient's goal of achieving a lower level of alcohol consumption. The medication is considered relevant for adults with alcohol dependence who have a high drinking risk level but do not have physical withdrawal symptoms.

The medication is applied across conditions characterized by alcohol dependence and high drinking risk level (DRL). The medication helps manage the psychological symptom of compulsive urge or craving that drives excessive drinking, and is relevant for managing the symptomatic manifestations of Heavy Drinking Days (HDD).

It is commonly applied in clinical settings to facilitate a patient-controlled risk reduction approach. This strategy is relevant for patients who seek to reduce consumption incrementally and is applicable in contexts involving continuous psychosocial support. This pharmacotherapy provides supportive relief that may assist with maintaining functional stability while addressing consumption goals.

Quick Fact: Support for Compulsive Urge
Selincro is relevant for easing the intense psychological drive associated with excessive consumption, which may assist with maintaining a sense of stability during periods associated with high-risk drinking.

Regulatory References

1. European Medicines Agency (EMA) product overview

Selincro (nalmefene) is strictly indicated for adult patients (ge 18 years of age) with alcohol dependence who have a high drinking risk level (DRL) and who are receiving continuous psychosocial support. It is intended for those who seek to reduce, but not immediately stop, alcohol consumption, and it must not be used in patients presenting with physical alcohol withdrawal symptoms or requiring immediate detoxification.

Contraindications and Restrictions

Official regulatory labeling dictates several absolute contraindications where Selincro must not be used:

Contraindication	Condition	Restriction Status
Opioid Use	Patients taking opioid agonists (e.g., methadone or strong analgesics) or with current/recent opioid addiction	Contraindicated
Organ Function	Patients with severe hepatic impairment (Child-Pugh Class C) or severe renal impairment	Contraindicated
Alcohol Withdrawal	Recent history of acute alcohol withdrawal syndrome (including seizures or delirium tremens)	Contraindicated

Use is not recommended in the pediatric population (under 18 years) as safety and efficacy have not been established. Furthermore, the medicine is not recommended for use during pregnancy or lactation. Caution should be exercised when prescribing to patients with mild-to-moderate renal or hepatic impairment.

The interaction profile for nalmefene (Selincro) is defined by its effects on opioid receptors and its metabolic pathway through UGT enzymes, as documented in official regulatory labeling.

Contraindicated Drug Combinations

The co-administration of nalmefene with any opioid agonist is formally contraindicated due to the risk of pharmacodynamic antagonism. This restriction applies to all opioid analgesics, partial opioid agonists (such as buprenorphine), and opioids used for substitution therapy (e.g., methadone). The result of this combination is the prevention of the intended therapeutic effect of the opioid medication.

Pharmacokinetic Interactions

Nalmefene is primarily cleared by the UGT2B7 enzyme. Co-administration with potent UGT2B7 inhibitors (e.g., diclofenac, fluconazole) may significantly increase nalmefene exposure (plasma concentrations). Conversely, co-administration with a UGT inducer (e.g., rifampicin, omeprazole) may lead to potentially subtherapeutic nalmefene plasma concentrations.

Timing and Administration Constraints

A mandatory administrative constraint requires nalmefene to be temporarily discontinued for one week prior to the anticipated need for opioid use, such as for elective surgery or pain management.

Food, Alcohol, and Population Notes

Official regulatory documents state there is no clinically relevant pharmacokinetic drug-drug interaction with alcohol. While a high-fat meal may increase nalmefene exposure, this change is officially categorized as unlikely to be of clinical relevance. Caution is advised when prescribing to patients with documented mild or moderate hepatic or renal impairment.

Modulation of the Opioid Reward System

Nalmefene functions as a selective opioid system modulator in the brain, primarily by acting as a strong antagonist (blocker) at the mu- and delta-opioid receptors and a partial agonist at the kappa -Opioid Receptor. This differential binding pattern is essential: it prevents the overactivation of mu -Opioid Receptors by endogenous opioids that mediate the positive reinforcement associated with alcohol consumption.

---

Dampening the Brain's Reinforcement Signal

The primary consequence of mu -opioid receptor blockade occurs within the mesolimbic reward pathway (the neural circuit spanning the VTA and NAc). By interrupting the signaling sequence, nalmefene indirectly attenuates the excessive dopamine release in the Nucleus Accumbens that typically follows heavy drinking. This physiological dampening of the reward signal attenuates the positive reinforcement generated by alcohol consumption.

---

Mechanistic Constraints

The action of nalmefene is chemically constrained by its high affinity for opioid receptors; consequently, the mechanism cannot operate in the presence of exogenous opioid dependence. Furthermore, the precise contribution of the delta - and kappa -opioid receptor activity to the full mechanistic action is still under scientific investigation.

Selincro is an orally administered medication available as a film-coated tablet containing 18 mg of nalmefene. The use of this drug is defined by a specific intermittent dosing schedule tied to anticipated drinking events, rather than a continuous daily regimen. The standard adult dose is one 18 mg tablet per administration, and this dose must not exceed more than once within a 24-hour period.

The administration protocol specifies taking one tablet 1 to 2 hours prior to the time the patient expects to begin consuming alcohol. The tablet should be swallowed whole and can be taken with or without food, as there are no restrictions on meal timing. If a dose is missed—meaning the patient begins drinking without having taken the tablet—the dose should be taken as soon as possible, provided the single-dose limit per day is respected.

Usage is further constrained by the mandatory requirement that Selincro must be initiated and maintained in conjunction with continuous psychosocial support aimed at helping the patient reduce alcohol consumption. Regarding specific populations, no dose adjustment is necessary for older adults, but use is generally not recommended in patients with severe hepatic or severe renal impairment. The necessity for continuing treatment should be professionally reviewed after the first six weeks.

Research Evidence / Overview of Studies for Selincro (Nalmefene)

---

Research Examining Consumption Measurements

The evidence landscape for this compound is built primarily upon several controlled clinical trials that examined patients with alcohol dependence to monitor consumption measurements. These studies were used in research exploring how patients with alcohol dependence change their consumption over defined time intervals. In these trials, researchers examined the compound alongside required psychosocial support, comparing these results against patients who received a placebo (an inactive tablet) also alongside the same psychosocial support.

The studies monitored changes in key measurements, known as surrogate endpoints, which included the monthly Number of Heavy Drinking Days (HDD) and the Total Alcohol Consumption (TAC), measured in grams of alcohol per day. Research describes how these consumption patterns evolved in the observed populations. These findings describe patterns observed in the studies and contribute to the broader evidence landscape regarding how consumption is measured.

The specific analysis of findings was most relevant to the authorized indication. This specific analysis focused on adults who had high alcohol consumption levels and did not have physical withdrawal symptoms. The research describes patterns in both the number of heavy drinking days and the overall amount of alcohol consumed over the study periods.

---

Long-Term Studies and Follow-Up Data

The research conducted so far explored short-term symptom changes, with the primary follow-up durations for the pivotal trials lasting about six months. One longer-term study monitored responses over a defined time interval of approximately one year. This evidence helps contextualize how patients reported their experience during intermediate treatment periods.

Limited information is available for long-term outcomes extending beyond one year. Research examined whether the measured consumption patterns were sustained throughout the longer observation periods. However, long-term effects on major health outcomes, such as rates of severe illness or injury, are not fully established by the existing controlled studies.

---

Understanding the Research Limitations and Uncertainty

One notable research limitation is the fact that the findings most relevant to the authorized indication were based on subgroup analyses—meaning the analysis was performed after the trial was complete, focusing on a specific, targeted patient group, rather than the original, full population.

Furthermore, because researchers focused on consumption metrics (HDD and TAC), these are considered surrogate endpoints. The existing research provides limited insight into whether changes in these consumption metrics translate directly into tangible reductions in long-term health risks, such as mortality or organ damage. Comparative evidence is also limited against other pharmacotherapies for this condition.

Key Studies & References

1. Nalmefene for reducing alcohol consumption in people with alcohol dependence | NICE Final appraisal determination
2. Risks and Benefits of Nalmefene in the Treatment of Adult Alcohol Dependence: A Systematic Literature Review and Meta-Analysis of Published and Unpublished Double-Blind Randomized Controlled Trials (Palpacuer et al.)

Common questions about Selincro (FAQ)

Q: Is Selincro prescribed for anxiety or depression?

A: According to official product information, the authorized indication for the active substance Nalmefene is strictly for the reduction of alcohol consumption in adult patients who have a high drinking risk level. The medication is not approved for the treatment of psychiatric disorders such as anxiety or depression.

Q: Can Selincro cause changes in mood?

A: Regulatory documents note that mood and mental state reactions have been reported. Commonly reported reactions include restlessness, a confusional state, and decreased libido. Rarer reactions include hallucination and dissociation. These reactions are generally reported as mild or moderate and are often temporary.

Q: Are there any long-term side effects associated with Selincro use?

A: The majority of documented adverse reactions are mild to moderate and tend to occur when treatment is first started, often resolving within a few days. Official studies primarily focused on intermediate treatment periods, and limited information is available for safety and effectiveness outcomes that extend beyond approximately one year of controlled use.

Q: Does Selincro interact with common painkillers like ibuprofen?

A: The medication is metabolized by a liver enzyme called UGT2B7. Official product information advises caution with medicines known as potent UGT2B7 inhibitors, such as diclofenac, as they may increase the amount of Nalmefene in the blood. The official product information states that the healthcare provider should be consulted regarding how Selincro may interact with other medicines.

Q: Can women use Selincro in the same way as men?

A: Official pharmacokinetic data indicates that Nalmefene does not exhibit substantial differences in how it is processed by the body between sexes, meaning no general dose adjustment is needed for adult women. However, the medication is not recommended for use during pregnancy or breastfeeding, as detailed in the official restrictions.

Q: Is there a generic version of Selincro available?

A: The active substance is Nalmefene. It is currently marketed under the brand name Selincro for this specific indication in authorized countries within the EU and UK.

Q: How quickly does Selincro start to have an effect?

A: The administration protocol is designed for event-driven use. Regulatory instructions specify that one tablet should be taken 1 to 2 hours prior to the time the patient anticipates starting to consume alcohol.

Q: Is Selincro a type of narcotic or controlled substance?

A: Nalmefene is classified as an opioid system modulator and antagonist. It is regulated by health authorities as a Prescription-only Medicine (POM) in the territories where it is authorized, but it is not typically categorized as a federally scheduled controlled substance.

Q: Does Selincro work for everyone who takes it?

A: Individual response to pharmacotherapies varies, and not every patient will experience the same result. Official documents state that the necessity for continuing treatment must be professionally reviewed after the first six weeks to assess whether the patient is benefiting from the treatment.

Q: Is it possible to become dependent on Selincro?

A: Nalmefene is an opioid receptor antagonist, meaning it works by blocking certain signals in the brain. According to official product documents, there is no known potential for dependence or abuse associated with this medication.

Q: Is Selincro used outside of Europe and the UK?

A: The oral tablet formulation (Selincro) is authorized for this specific use in the European Union and the United Kingdom. Official records indicate that the tablet formulation is not available for this alcohol-related indication in the United States.

Q: Why is Selincro not recommended for people who are fully abstinent?

A: Regulatory guidelines state that the medication is not intended for patients for whom the treatment goal is immediate or mandatory abstinence. The drug works by modulating the brain’s reward system during drinking events, making it relevant only for those who seek to reduce their overall consumption.

Q: What if I accidentally take two Selincro tablets?

A: The maximum recommended dose is strictly limited to one tablet within a 24-hour period. While specific symptoms of an oral overdose are not fully established in product information, official product information states that the management of an overdose involves symptomatic and supportive measures.

Q: Is Selincro safe for people with a history of seizures?

A: The medicine is formally contraindicated for use in patients with a recent history of acute alcohol withdrawal syndrome, including seizures. Furthermore, official product documents state that caution is advised for use in patients with any history of seizure disorders.

Q: Are there any restrictions on combining Selincro with herbal supplements?

A: Caution is advised regarding the co-administration of Nalmefene with other substances. Regulatory documents advise caution when taking other medicinal products, including over-the-counter medicines and dietary supplements, as they may have an impact on the drug’s metabolism.

Q: Has Selincro been withdrawn from any markets?

A: Official regulatory records show that the Nalmefene injection form (marketed as Revex) was withdrawn from the US market in 2008 for business reasons only. The oral tablet formulation (Selincro) remains authorized and available in the European Union and UK.

Q: What is the official recommended duration for Selincro treatment?

A: Official product information details a key administrative constraint regarding the duration of use. The necessity for continuing treatment must be professionally reviewed after the first six weeks to determine the benefit to the patient.

Q: How long does Selincro stay in your system?

A: Pharmacokinetic data from official sources describes the elimination of the active substance, Nalmefene. It has a mean terminal elimination half-life of approximately 10.8 hours.

Q: Is Selincro a first-line treatment option?

A: The medication is an authorized treatment option for eligible adult patients who meet specific criteria and are receiving continuous psychosocial support. It is recognized as one of the pharmacotherapies available for this condition.

Q: Can Selincro be used by people with a history of psychosis?

A: Official documents note that psychiatric reactions such as confusion, dissociation, and hallucinations have been reported. Due to these potential effects, regulatory guidelines state that caution is advised for use in patients with co-morbid psychiatric disease.

How to Store and Dispose of Selincro

Official regulatory documents define the storage and disposal requirements for Selincro (nalmefene) tablets.

Requirement	Official Regulatory Statement
Storage Conditions	Do not require any special storage conditions.
Shelf Life	3 years.
Packaging	Keep in the original packaging (PVC/PVdC-aluminium blisters).
Child Safety	Keep out of the sight and reach of children.

This medication is stable at room temperature and has a 3-year shelf life when maintained in its protective blister packaging. For safety, the product must be kept out of the sight and reach of children. Disposal instructions mandate that any unused medicinal product or waste material be discarded in accordance with local requirements for pharmaceutical waste.